thymosin beta-4 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-18. Numbers and descriptions here follow the published literature rather than marketing material.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
=== Identifying malnourishment === Measuring children is crucial to identifying malnourishment. In 2000, the United States Centers for Disease Control and Prevention (CDC) established the International Micronutrient Malnutrition Prevention and Control (IMMPaCt) program. It tested children for malnutrition by conducting a three-dimensional scan, using an iPad or a tablet. Its objective was to help doctors provide more efficient treatments. There may be some chance of error when using this method. The Screening Tool for the Assessment of Malnutrition in Paediatrics (STAMPa) is another method for the identification and evaluation of malnutrition in young children. The assessment tool has fair to medium reliability in the identification of children at risk of malnutrition. A systematic review of 42 studies found that many approaches to mitigating acute malnutrition are equally effective; thus, intervention decisions can be based on cost-related factors. Overall, evidence for the effectiveness of acute malnutrition interventions is not robust. The limited evidence related to cost indicates that community and outpatient management of children with uncomplicated malnutrition may be the most cost-effective strategy. Regularly measuring and charting children's growth and including activities to promote health (an intervention called growth monitoring and promotion, also known as GPM) is often considered by policy makers and is recommended by the World Health Organization. This program is often performed at the same time as a child has their regular immunizations.
The first of these incursions occurred when a fleet of these Crusaders was invited by the Portuguese king Afonso I Henriques to conquer the city of Lisbon in 1142. Although this Siege of Lisbon (1142) was a failure it created a precedent for their involvement in Portugal. So in 1147 when another group of Norman and other groups of crusaders from Northern Europe arrived in Porto on their way to join the crusading forces of the Second Crusade, the Bishop of Porto and later Afonso Henriques according to De expugnatione Lyxbonensi convinced them to help with the siege of Lisbon. This time the city was captured and according to the arrangement agreed upon with the Portuguese monarch many of them settled in the newly sacked city. The following year the remainder of the crusading fleet, including a substantial number of Anglo-Normans, was invited by the count of Barcelona, Ramon Berenguer IV, to participate in the siege of Tortosa (1148). Again the Normans were rewarded with lands in the newly conquered frontier city.
There are specific proteins expressed in cardiac muscle cells. These are mostly associated with muscle contraction, and bind with actin, myosin, tropomyosin, and troponin. They include MYH6, ACTC1, TNNI3, CDH2 and PKP2. Other proteins expressed are MYH7 and LDB3 that are also expressed in skeletal muscle.
Snake venom is a highly toxic saliva containing zootoxins that facilitates in the immobilization and digestion of prey. This also provides defense against threats. Snake venom is usually injected by unique fangs during a bite, though some species are also able to spit venom. The venom glands that secrete zootoxins are a modification of the parotid salivary glands found in other vertebrates and are usually located on each side of the head, below and behind the eye, and enclosed in a muscular sheath. The venom is stored in large glands called alveoli before being conveyed by a duct to the base of channeled or tubular fangs through which it is ejected. Venom contains more than 20 different compounds, which are mostly proteins and polypeptides. The complex mixture of proteins, enzymes, and various other substances has toxic and lethal properties. Venom serves to immobilize prey. Enzymes in venom play an important role in the digestion of prey, and various other substances are responsible for important but non-lethal biological effects. Some of the proteins in snake venom have very specific effects on various biological functions, including blood coagulation, blood pressure regulation, and transmission of nerve or muscle impulses. These venoms have been studied and developed for use as pharmacological or diagnostic tools, and even drugs.
Sources: en.wikipedia.org
=== Excess facial hair in women === The topical cream is indicated for treatment of facial hirsutism in women. It is the only topical prescription treatment that slows the growth of facial hair. In clinical studies with Vaniqa, 81% of women showed clinical improvement after twelve months of treatment. Positive results were seen after eight weeks. However, discontinuation of the cream caused regrowth of hair back to baseline levels within 8 weeks. Vaniqa treatment significantly reduces the psychological burden of facial hirsutism.
Founder Jeffery Tripp opened the first Pretzelmaker store in 1991. He changed the name of the company to Pretzelmaker for nationwide franchising purposes. Charles L. Smith was the founding president of Pretzelmaker, Corporation with Bruce W. Stratford, Legal Council and CFO. J. Kelly Hansen and Stephen A. Thorpe ran the day-to-day operations as co-founders and VP of Sales and VP of Operations respectively. The brand quickly grew to more than 100 franchises sold, with 40 stores operating by 1995 when it was bought by a group of investors that helped make Pretzelmaker a mall mainstay, particularly in the West Coast. Don Cox, Marc Geman, Tony Joseph and Dale Fowler bought the company in 1995 with a small group of investors. In the next 36 months this group took the company from 11 opened stores to 288. Director of Operations Tony Joseph and his operation team were the driving force opening 7 locations a month. Mr. Joseph trained all franchisees US wide, Canada, South Korea, Thailand, Hong Kong and Singapore. In 1998 Pretzelmaker was voted the fastest growing food Franchise in the US according to Restaurant News and Entrepreneur Magazine. Dale Fowler was the Sr. Vice President of Marketing. Mr. Fowler put Pretzelmaker on the map with Media articles from the top newspapers and magazines from all over the US. Don Cox was the President until he was relieved of his duties in 1998. Marc Geman was the CEO until the company was sold in 1999.
CaO + H2O → Ca(OH)2 Ca(OH)2 + CO2 → CaCO3 + H2O Calcium carbonate can be crystallized from calcium chloride (CaCl2), by placing an aqueous solution of CaCl2 in a desiccator alongside ammonium carbonate [NH4]2CO3. In the desiccator, ammonium carbonate is exposed to air and decomposes into ammonia, carbon dioxide, and water. The carbon dioxide then diffuses into the aqueous solution of calcium chloride, reacts with the calcium ions and the water, and forms calcium carbonate.
== ICH GCP overview == Glossary Principles of ICH GCP Guidelines for: institutional review board (IRB) / independent ethics committee (IEC) investigator trial sponsor (industrial, academic) clinical trial protocol and protocol amendments investigator's brochure essential documents
=== History of mid to large scale oligonucleotide synthesis === Large scale oligonucleotide synthesizers were often developed by augmenting the capabilities of a preexisting instrument platform. One of the first mid scale synthesizers appeared in the late 1980s, manufactured by the Biosearch company in Novato, CA (The 8800). This platform was originally designed as a peptide synthesizer and made use of a fluidized bed reactor essential for accommodating the swelling characteristics of polystyrene supports used in the Merrifield methodology. Oligonucleotide synthesis involved the use of CPG (controlled pore glass) which is a rigid support and is more suited for column reactors as described above. The scale of the 8800 was limited to the flow rate required to fluidize the support. Some novel reactor designs as well as higher than normal pressures enabled the 8800 to achieve scales that would prepare 1 mmol of oligonucleotide. In the mid 1990s several companies developed platforms that were based on semi-preparative and preparative liquid chromatographs. These systems were well suited for a column reactor approach. In most cases all that was required was to augment the number of fluids that could be delivered to the column. Oligo synthesis requires a minimum of 10 and liquid chromatographs usually accommodate 4. This was an easy design task and some semi-automatic strategies worked without any modifications to the preexisting LC equipment. PerSeptive Biosystems as well as Pharmacia (GE) were two of several companies that developed synthesizers out of liquid chromatographs.
Sources: en.wikipedia.org
== Preparation == To make a gelatine dessert, gelatine is dissolved in hot liquid with the desired flavours and other additives. These latter ingredients usually include sugar, fruit juice, or sugar substitutes; they may be added and varied during preparation, or pre-mixed with the gelatine in a commercial product which mainly requires the addition of hot water. In addition to sweeteners, the prepared commercial blends generally contain flavouring agents and other additives, such as adipic acid, fumaric acid, sodium citrate, and artificial flavourings and food colours. Because the collagen is processed extensively, the final product is not categorised as a meat or animal product by the United States federal government.
Lilly tried several product line extension strategies, including extended-release formulations and paying for clinical trials to test the efficacy and safety of fluoxetine in premenstrual dysphoric disorder and rebranding fluoxetine for that indication as "Sarafem" after it was approved by the FDA in 2000, following the recommendation of an advisory committee in 1999. The discovery of using fluoxetine to treat PMDD was made by Richard Wurtman at MIT; the patent was licensed to his startup, Interneuron, which in turn sold it to Lilly. To defend its Prozac revenue from generic competition, Lilly also fought a five-year, multimillion-dollar battle in court with the generic company Barr Pharmaceuticals to protect its patents on fluoxetine, and lost the cases for its line-extension patents, other than those for Sarafem, opening fluoxetine to generic manufacturers starting in 2001. When Lilly's patent expired in August 2001, generic drug competition decreased Lilly's sales of fluoxetine by 70% within two months. In 2000 an investment bank had projected that annual sales of Sarafem could reach $250 million. Sales of Sarafem reached about $85 million in 2002, and in that year Lilly sold its assets connected with the drug for $295 million to Galen Holdings, a small Irish pharmaceutical company specializing in dermatology and women's health that had a sales force tasked to gynecologists' offices; analysts found the deal sensible since the annual sales of Sarafem made a material financial difference to Galen, but not to Lilly.
=== Functional and bioactive components === Among the functional proteins detected in donkey milk, there are molecules active in antimicrobial protection such as lysozyme and lactoferrin. The lactoferrin content of donkey milk is intermediate between the lower values of cow milk and the higher values of human milk. Lactoferrin inhibits the growth of iron-dependent bacteria in the gastrointestinal tract. This inhibits certain organisms, such as coliforms and yeast, that require iron. Lysozyme in donkey milk is present in large amounts, and ranges from 1.0 mg/mL to 4 mg/mL, depending on the analytical method used (chemical or microbiological); This substance is present also in humans (0.12 mg/mL) but only in trace amounts in cow and goat milk. Lysozyme in donkey milk is highly thermo-stable and is very resistant to acid and protease and may play a significant role in the intestinal immune response. In donkey mammary secretion, defatted or not, growth factors and hormones have also been determined. Donkey mammary secretions contain human-like leptin at levels close to human milk (3.35 e 5.32 ng/mL milk). The bioactive peptides insulin-like growth factor 1, ghrelin, and triiodothyronine were also found in frozen donkey milk. These molecules and many others present in human milk, are increasingly receiving attention from a nutraceutical point of view because of their potential direct role in regulating food intake, metabolism, and infant body condition.
"You have the bad luck of meeting a man who knows a lot about history (...) While we lost six thousand men and part of the national territory [in the War of the Pacific], you took advantage of the precise moment to peacefully conquer La Patagonia (...) Now you want Peru to enter the war, but later, while Chile and Argentina make up, we lose Arequipa" In the 20th century, given the significant presence of illegal Peruvian immigrants in Argentina, to avoid their massive expulsion, the governments of both countries agreed to sign a reciprocal Migration Agreement in August 1998, which would make it possible to regularize the situation of Argentine migrants and Peruvians in the host country, granting a period of 180 days for this. The bilateral agreement will recognize the rights of the Peruvian worker in Argentina, but only up to a period of 12 months, after which he must undergo an Immigration Law, which various sectors of the opposition, as well as the Church in Argentina, had described as xenophobic and racist with anti-Peruvian overtones. Another of the institutions that showed a special interest in the migratory situation of Peruvians was the Commission of Peruvian Ladies Resident in Argentina, chaired by Mrs. Carmen Steimann. In a meeting organized by the Peruvian community in Buenos Aires, Ms. Steimann would protest the attitude of the Argentine Gendarmerie, accusing them of carrying out an obsessive and cruel persecution of immigrants, mostly just for being Peruvian and Bolivian.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.